2017
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Wesolowski R, Duggan M, Stiff A, Markowitz J, Trikha P, Levine K, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae E, Lustberg M, Reinbolt R, Mrozek E, Byrd J, Caligiuri M, Mace T, Carson W. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy 2017, 66: 1437-1447. PMID: 28688082, PMCID: PMC5647220, DOI: 10.1007/s00262-017-2038-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlack or African AmericanBreast NeoplasmsCell CountChemotherapy, AdjuvantCyclophosphamideCytokinesDoxorubicinFemaleGranulocytesHumansMiddle AgedMonocytesMyeloid-Derived Suppressor CellsNeoadjuvant TherapyPaclitaxelPilot ProjectsTreatment OutcomeWhite PeopleConceptsMyeloid-derived suppressor cellsPathologic complete responseG-MDSC levelsNeo-adjuvant chemotherapyG-MDSCSuppressor cellsComplete responseAnti-HER2 therapyPeripheral blood levelsBreast cancer patientsAfrican American patientsBreast cancer typesCyclophosphamide therapyBlood levelsCancer patientsLast administrationAmerican patientsBreast cancerPatientsFlow cytometryCancer typesChemotherapySignificant riseConfidence intervalsCycle 1
2016
Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer
Himmel L, Lustberg M, DeVries A, Poi M, Chen C, Kulp S. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Experimental And Toxicologic Pathology 2016, 68: 505-515. PMID: 27555377, PMCID: PMC5203928, DOI: 10.1016/j.etp.2016.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBlotting, WesternCell Line, TumorCell SurvivalCognition DisordersCyclophosphamideDNA DamageDoxorubicinFemaleHumansImmunohistochemistryMiceMice, NudeMinocyclineNeuroprotective AgentsTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysConceptsTriple-negative breast cancerChemotherapy-induced cognitive impairmentBreast cancer patientsNeural progenitor cellsPutative neuroprotectantCancer patientsBreast cancerXenograft modelDoublecortin-positive neural progenitor cellsFemale athymic nude miceDoxorubicin-cyclophosphamide chemotherapyProgenitor cellsEffects of minocyclineChemotherapeutic drug combinationsOrgan weight measurementsAbsence of minocyclineAthymic nude miceTNBC cell linesTumor-bearing miceAnti-oxidant pathwaysTumor-suppressive effectsBiomarkers of apoptosisTumor volume measurementsHuman neurologic diseasesMechanism of action
2015
Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer
Oostra D, Lustberg M, Reinbolt R, Pan X, Wesolowski R, Shapiro C. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. Molecular And Cellular Endocrinology 2015, 402: 51-56. PMID: 25575458, PMCID: PMC4316829, DOI: 10.1016/j.mce.2014.12.028.Peer-Reviewed Original ResearchConceptsBone mineral densityRapid bone lossFollicle stimulating hormoneBone lossAdjuvant chemotherapyOPG levelsFemoral neckBone resorptionBreast cancerLumbar spineStage I/II breast cancerLS bone mineral densityEarly-stage breast cancerAssociation of osteoprotegerinMonths of amenorrheaMIU/mLNegative pregnancy testNuclear factor kappaChemotherapy initiationPremenopausal womenFSH levelsOsteoclast activationMineral densityStimulating hormonePregnancy test
2013
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy
Wenzell C, Berger M, Blazer M, Crawford B, Griffith N, Wesolowski R, Lustberg M, Phillips G, Ramaswamy B, Mrozek E, Flynn J, Shapiro C, Layman R. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Supportive Care In Cancer 2013, 21: 2845-2851. PMID: 23748485, PMCID: PMC3769492, DOI: 10.1007/s00520-013-1865-9.Peer-Reviewed Original ResearchConceptsDay 1Emetogenic chemotherapyCR rateDay 2Doxorubicin/cyclophosphamide chemotherapyPilot studyOverall complete responseSame patient populationAntiemetic regimenAntiemetic regimensPAD armCyclophosphamide chemotherapyPrimary endpointFeared complicationComplete responseProspective studyPatient populationResultsA totalBreast cancerPatientsRegimensChemotherapyOverall CROndansetronDescriptive statistics